Research Article
Dupilumab: Direct Cost and Clinical Evaluation in Patients with Atopic Dermatitis
Table 3
Comparison of clinical outcomes pre- and posttherapy with Dupilumab.
| | At baseline | At the end of observation period | value |
| Median (IQR) EASI at baseline | 31 (25–40) | 5 (1–10) | <0.0001 | Median (IQR) DLQI at baseline | 10 (10–25) | 3 (1–5) | <0.0001 | Median (IQR) NRS at baseline | 10 (8–10) | 2 (1–3) | <0.0001 |
|
|